Cross-Sector entity
Zacks is most often covered alongside FiscalAI, which appears in 3 of these 7 stories. That works out to roughly 2.4 stories per week across a 20-day span. The busiest single day carried 2. The clearest coverage concentration is earnings: 4 of 7 stories, with the rest divided among 3 other categories.
7 verified stories tracked
Last mentioned: 3d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Zacks is most often covered alongside FiscalAI, which appears in 3 of these 7 stories. That works out to roughly 2.4 stories per week across a 20-day span. The busiest single day carried 2. The clearest coverage concentration is earnings: 4 of 7 stories, with the rest divided among 3 other categories. This profile follows 7 Cross-Sector stories mentioning Zacks across the period from August 3, 2026 to August 22, 2026. 0% of these stories carry negative sentiment. The tracked stories average 2 original sources each.
Computed from the 7 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Zacks. Shared-story counts are live from our verified record — not editorial picks.
Two micro-caps reported late-August earnings: biotech I-Mab posted $(0.16) EPS while CreditRiskMonitor posted $(0.04) EPS on $5.17M revenue. Divergent risk profiles—1.47 beta vs 0.22 beta—highlight small-cap earnings dynamics.
I-Mab, a clinical-stage oncology and immunology biotech, reported a $(0.16) quarterly EPS on Aug 20. With shares at $1.91, H.C. Wainwright's reiterated $9 target implies massive upside, though Weiss remains bearish. Institutional ownership sits at 38.38%.
Source: Bbns · Ticker Report
Seneca Foods posted a top-line beat of $405.17M, 24% above estimates, despite a $0.07 EPS miss, driving a 7.4% stock surge and Strong Buy ratings. Talkspace, meanwhile, missed on both EPS and revenue, but its stock held steady as institutional investors continued accumulating shares.
Source: themarketsdaily.com · dailypolitical.com
Atlanticus Holdings (ATLC) delivered a $2.50 EPS, beating by $0.08, on solid profitability metrics. Simultaneously, insiders including the CFO sold $7.87 million in shares, raising questions about alignment. With a P/E of 16.69 and beta of 2.11, the stock remains a volatile play in consumer credit.
Aligos Therapeutics (ALGS) handily beat Q2 consensus earnings per share by $0.95, a significant outperformance for the clinical-stage biotech. This beat may reflect operational efficiencies, milestone payments, or clinical progress in its liver disease pipeline. Investors in the biotech space should watch for full financial disclosures to gauge the sustainability of this positive surprise.
Source: dailypolitical.com · themarketsdaily.com
CPKC's Q2 earnings beat, with revenue up 12.6% to $2.93 billion, highlights robust cross-border rail demand. For supply chain professionals, the performance reflects strong trade flows and network integration benefits post-merger.
Canadian Pacific Kansas City posted a $0.03 EPS beat and 12.6% revenue growth, maintaining strong margins. With a consensus Buy rating and price targets as high as $105, the stock offers a defensive growth story for investors.
Source: themarketsdaily.com · dailypolitical.com
